Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Dec;10(4):487-99.
doi: 10.1007/s11523-015-0368-7.

Renal Toxicities of Targeted Therapies

Anum Abbas  1 , Mohsin M Mirza  1 , Apar Kishor Ganti  2 , Ketki Tendulkar  3
Affiliations
Review

Renal Toxicities of Targeted Therapies

Anum Abbas et al. Target Oncol. 2015 Dec.

Abstract

With the incorporation of targeted therapies in routine cancer therapy, it is imperative that the array of toxicities associated with these agents be well-recognized and managed, especially since these toxicities are distinct from those seen with conventional cytotoxic agents. This review will focus on these renal toxicities from commonly used targeted agents. This review discusses the mechanisms of these side effects and management strategies. Anti-vascular endothelial growth factor (VEGF) agents including the monoclonal antibody bevacizumab, aflibercept (VEGF trap), and anti-VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKIs) all cause hypertension, whereas some of them result in proteinuria. Monoclonal antibodies against the human epidermal growth factor receptor (HER) family of receptors, such as cetuximab and panitumumab, cause electrolyte imbalances including hypomagnesemia and hypokalemia due to the direct nephrotoxic effect of the drug on renal tubules. Cetuximab may also result in renal tubular acidosis. The TKIs, imatinib and dasatinib, can result in acute or chronic renal failure. Rituximab, an anti-CD20 monoclonal antibody, can cause acute renal failure following initiation of therapy because of the onset of acute tumor lysis syndrome. Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, can result in proteinuria. Discerning the renal adverse effects resulting from these agents is essential for safe treatment strategies, particularly in those with pre-existing renal disease.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Clin Cancer Res. 2009 Oct 1;15(19):6232-40 - PubMed
    1. J Clin Oncol. 2012 Mar 10;30(8):863-70 - PubMed
    1. Ren Fail. 2010 Jan;32(1):147-9 - PubMed
    1. N Engl J Med. 2009 Jul 9;361(2):211-2 - PubMed
    1. N Engl J Med. 2006 May 11;354(19):2006-13 - PubMed

MeSH terms

Substances

LinkOut - more resources